Tuesday October 29 8:19 AM EDT
ImmuDyne Announces Ongoing Discussions Between
Parties in Shareholder Lawsuit
HOUSTON--(BUSINESS WIRE)--Oct. 29, 1996--ImmuDyne, Inc. (NASDAQ:IMMD)
announced today that settlement discussions are ongoing regarding the cases styled Mark
McLaughlin and Tom McCarvill v. ImmuDyne, Inc., Byron A. Donzis, James D. Wood and
Carmel Research, Inc., Cause No. 94-CI-035664 in the 225th Judicial District Court, Bexar
County, Texas and ImmuDyne, Inc., Byron A. Donzis and James D. Wood v. Mark W.
McLaughlin, Cause No. H-95-5845, in the United States District Court, Southern District of
Texas, Houston Division.
Although a definitive statement cannot be made, ImmuDyne is cautiously optimistic that an
agreement can be reached and will make further announcements as information becomes available.
ImmuDyne, Inc. is listed on the NASD Automated Bulletin Board with the symbol IMMD.
ImmuDyne, Inc. is a Texas-based biotechnology company specializing in macrophage technology.
It has patented technology relating to immune system stimulants for pharmaceutical, cosmetic,
nutritional, veterinary and agricultural use. ImmuDyne, Inc. maintains offices in Houston and Palo
Alto, California. For more information on the company, contact Margaret Dreyfus, at
415/949-3864.
CONTACT: ImmuDyne, Inc.
Margaret Dreyfus, 415/949-3864 |
